BEAT-AML trial provides proof of principle for a precision medicine for pts aged >60 yrs with AML: 95% has molecular profiling completed within 7 days and 30-day mortality was lower in the 57% of pts who received targeted therapy (3.7% vs 20.4% with SOC)
Part 2 of an awesome week of great collaborative studies coming out; the Beat AML Master Trial! An amazing effort led by Amy Burd , John Byrd , Brian Druker and myself .
Online now – Treatment of #leukemia patients based on genomic profiling is feasible and improves patients' outcomes. Initial results from the Beat AML umbrella #Clinicaltrial 👉🏾 #precisionmedicine
Results from a study published in by Winship investigators William Blum, MD, Martha Arellano, MD, and colleagues show that older patients with AML can benefit from using genetic information to match patients to targeted therapies. #leusm
#PrecisionMedicine Tx in AML using prospective genomic profiling: feasibility & preliminary efficacy of the Beat AML Master Trial [Oct 26, 2020] Burd et al. #AMLsm #leusm #NCT03013998 n=395 >=60yo 1L AML. Improved OS
#Precision #medicine treatment in acute myeloid leukemia (#AML)
This report in Nature Medicine, summarizes up-to-date findings of Beat AML, a trial incorporating genomic data into treatment decisions. Overall survival was significantly longer in patients matched to treatments than those receiving SOC.
#PrecisionMedicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial [Oct 26, 2020] Amy Burd et al #AMLsm #leusm #NCT03013998